Peripheral anti-hyperalgesia by oxcarbazepine: Involvement of adenosine A 1 receptors

Pharmazie

Volumn 61, Issue 6, 2006, Pages 566-568

  Tomić, Maja A ^a,c   Vuckovic S M ^a   Stepanovic Petrovic R M ^a   Ugresic N ^a   Prostran, M S ^a   Boskovic B ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Military Medical Academy   (Serbia)

^c Faculty of Pharmacy   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; CONCANAVALIN A; OXCARBAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; RAT;

EID: 33745624612     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Aley KO, Green PG, Levine JD (1995) Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. J Neurosci 15: 8031-8038.
2. 1 antinociception, tolerance, and withdrawal. J Neurosci 17: 735-744.
3. 1 receptors very similar to those of peripheral tissues. Eur J Pharmacol 196: 313-317.
4. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27: 121-130.
5. Carrazana E, Mikoshiba I (2003) Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 25: S31-S35.
6. Cottney J, Lewis AJ (1975) Mechanisms of concanavalin A-induced inflammation in the rat. Br J Pharmacol 53: 445.
7. 2 ) receptors. Psychopharmacology 90: 332-335.
8. Kiguchi S, Ichikawa K, Kojima M (2001) Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats. Clin Exp Pharmacol Physiol 28: 169-175.
9. Kiguchi S, Imamura T, Ichikawa K, Kojima M, Shibata N (2002) Antinociceptive effect of oxcarbazepine (KIN-493/OCBZ) in diabetic animals and its pharmacological properties. Pharmacologist 44: A54.
10. Kiguchi S, Imamura T, Ichikawa K, Kojima M (2004) Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin Exp Pharmacol Physiol 31: 57-64.
11. Marangos PJ, Post RM, Patel J, Zander K, Parma A, Weiss S (1983) Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur J Pharmacol 93: 175-182.
12. Sawynok J (1998) Adenosine receptor activation and nociception. Eur J Pharmacol 317: 1-11.
13. nd ed., New York, Berlin, Heidelberg, London, Paris, Tokyo.
14. Tomić MA, Vučković SM, Stepanović- Petrović RM, Ugrešić N, Prostran MS, Bošković B (2004) The anti-hyperalgesic effects of carbamazepine and oxcarbazepine are attenuated by treatment with adenosine receptor antagonists. Pain 111: 253-260.